Literature DB >> 10669529

The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma.

S B Liggett1.   

Abstract

The beta(2)-adrenergic receptor (beta(2)AR) is the molecular target for beta-agonists used in the treatment of asthma. In the human population, 4 polymorphisms of the beta(2)AR coding block have been found, 3 of which result in receptors that have different properties compared with wild-type. To date, clinical studies suggest that these beta(2)AR polymorphisms may alter asthmatic phenotype and the response to beta-agonist therapy, making these variants the first of undoubtedly several genetic loci that will ultimately be found that will provide for individualized therapy in asthma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10669529     DOI: 10.1016/s0091-6749(00)90048-4

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  24 in total

Review 1.  Genetic polymorphisms of adrenergic receptors.

Authors:  E M Garland; I Biaggioni
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

2.  RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications.

Authors:  Alberto J Alves; Nir Eynon; José Oliveira; Ehud Goldhammer
Journal:  World J Cardiol       Date:  2010-07-26

3.  Cholesterol modulates the dimer interface of the β₂-adrenergic receptor via cholesterol occupancy sites.

Authors:  Xavier Prasanna; Amitabha Chattopadhyay; Durba Sengupta
Journal:  Biophys J       Date:  2014-03-18       Impact factor: 4.033

4.  Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.

Authors:  C N A Palmer; B J Lipworth; S Lee; T Ismail; D F Macgregor; S Mukhopadhyay
Journal:  Thorax       Date:  2006-06-13       Impact factor: 9.139

5.  Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype.

Authors:  Erika J Sims; Catherine M Jackson; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

6.  Concomitant occasional use of salbutamol influences bronchoprotective responsiveness afforded by formoterol in patients with the glycine-16 genotype.

Authors:  Erika J Sims; Brian J Lipworth
Journal:  Eur J Clin Pharmacol       Date:  2003-12-11       Impact factor: 2.953

Review 7.  Benefit-risk assessment of long-acting beta2-agonists in asthma.

Authors:  Catherine M Jackson; Brian Lipworth
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.

Authors:  Daniel K C Lee; Graeme P Currie; Ian P Hall; John J Lima; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

9.  Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous beta2-adrenoceptor haplotypes at positions 16 and 27.

Authors:  Daniel K C Lee; Caroline E Bates; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

10.  Role of ADRB2 gene polymorphism in asthma and response to beta(2)-agonists in Polish children.

Authors:  A Szczepankiewicz; A Breborowicz; P Sobkowiak; L Kramer; A Popiel
Journal:  J Appl Genet       Date:  2009       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.